Skip to main content
Top
Gepubliceerd in: Quality of Life Research 7/2012

01-09-2012

The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy

Auteurs: Leah Kleinman, Katy Benjamin, Hema Viswanathan, Maria Stoeckl Mattera, Linda Bosserman, Douglas W. Blayney, Dennis A. Revicki

Gepubliceerd in: Quality of Life Research | Uitgave 7/2012

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To develop a patient-reported outcome instrument for measuring anemia symptoms and their impact in patients with chemotherapy-induced anemia (CIA).

Methods

Qualitative research was conducted using six focus groups and 24 interviews with 46 CIA patients, eight interviews in patients receiving chemotherapy with no CIA history and two interviews in patients successfully treated for CIA. Atlas.ti 5.0 was used to organize key concepts. Cognitive interviews with 16 CIA patients and assessment of relevance of each item to CIA by 10 clinicians were also conducted to evaluate content validity.

Results

Most CIA patients were white (76%) and female (83%), and the average age was 60 years. The most common cancer types were breast cancer (54%) and lung cancer (17%). Tiredness was the most prevalent symptom and rated as the most important by 83% of CIA patients; weakness, shortness of breath, lightheadedness, and dizziness were ranked next in importance. The final anemia impact measure (AIM) contains: (1) daily CIA symptom diary (9 items), and (2) impact of CIA-related tiredness (29 items covering daily living activities, social activities, cognitive function, and emotions). Cognitive interviews found that the AIM was relevant and easy to understand.

Conclusions

The AIM assesses important patient-perceived CIA symptoms and their impact and was developed using extensive patient qualitative data.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Groopman, J. E., & Itri, L. M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91(19), 1616–1634.PubMedCrossRef Groopman, J. E., & Itri, L. M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91(19), 1616–1634.PubMedCrossRef
2.
go back to reference Knight, K., Wade, S. & Balducci, L. (2004). Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med, 116(Suppl 7A), 11S–26S. Knight, K., Wade, S. & Balducci, L. (2004). Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med, 116(Suppl 7A), 11S–26S.
3.
go back to reference Merli, F., Bertini, M., Luminari, S., Mozzana, R., Berte, R., Trottini, M., et al. (2004). Quality of life assessment in elderly patients with aggressive non-Hodgkin’s Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica, 89(8), 973–978.PubMed Merli, F., Bertini, M., Luminari, S., Mozzana, R., Berte, R., Trottini, M., et al. (2004). Quality of life assessment in elderly patients with aggressive non-Hodgkin’s Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica, 89(8), 973–978.PubMed
4.
go back to reference Pujade-Lauraine, E. & Gascon, P. (2004). The burden of anaemia in patients with cancer. Oncology, 67(Suppl 1), 1–4. Pujade-Lauraine, E. & Gascon, P. (2004). The burden of anaemia in patients with cancer. Oncology, 67(Suppl 1), 1–4.
5.
go back to reference Bokemeyer, C. & Foubert, J. (2004). Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Semin Oncol, 31(3 Suppl 8), 4–11. Bokemeyer, C. & Foubert, J. (2004). Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Semin Oncol, 31(3 Suppl 8), 4–11.
6.
go back to reference Boccia, R., Lillie, T., Tomita, D., & Balducci, L. (2007). The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist, 12(5), 584–593.PubMedCrossRef Boccia, R., Lillie, T., Tomita, D., & Balducci, L. (2007). The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist, 12(5), 584–593.PubMedCrossRef
7.
go back to reference Berndt, E., Crown, W., Kallich, J., Long, S., Song, X., & Lyman, G. H. (2005). The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics, 23(2), 183–192.PubMedCrossRef Berndt, E., Crown, W., Kallich, J., Long, S., Song, X., & Lyman, G. H. (2005). The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics, 23(2), 183–192.PubMedCrossRef
8.
go back to reference Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T. & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117–124. Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T. & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117–124.
9.
go back to reference Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317–325.PubMedCrossRef Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317–325.PubMedCrossRef
10.
go back to reference Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology, 15(6), 979–986.PubMedCrossRef Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology, 15(6), 979–986.PubMedCrossRef
11.
go back to reference Berndt, E., Kallich, J., McDermott, A., Xu, X., Lee, H., & Glaspy, J. (2005). Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics, 23(5), 505–514.PubMedCrossRef Berndt, E., Kallich, J., McDermott, A., Xu, X., Lee, H., & Glaspy, J. (2005). Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics, 23(5), 505–514.PubMedCrossRef
12.
go back to reference Lyman, G. H., Berndt, E. R., Kallich, J. D., Erder, M. H., Crown, W. H., Long, S. R., et al. (2005). The economic burden of anemia in cancer patients receiving chemotherapy. Value Health, 8(2), 149–156.PubMedCrossRef Lyman, G. H., Berndt, E. R., Kallich, J. D., Erder, M. H., Crown, W. H., Long, S. R., et al. (2005). The economic burden of anemia in cancer patients receiving chemotherapy. Value Health, 8(2), 149–156.PubMedCrossRef
13.
go back to reference Seidenfeld, J., Piper, M., Bohlius, J., Weingart, O., Trelle, S., Engert, A., et al. (2006). Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative effectiveness review no. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Available at: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Seidenfeld, J., Piper, M., Bohlius, J., Weingart, O., Trelle, S., Engert, A., et al. (2006). Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative effectiveness review no. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Available at: http://​www.​effectivehealthc​are.​ahrq.​gov/​reports/​final.​cfm.
14.
go back to reference Bamias, A., Aravantinos, G., Kalofonos, C., Timotheadou, N., Siafaka, V., Vlahou, I., et al. (2003). Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology, 64(2), 102–110.PubMedCrossRef Bamias, A., Aravantinos, G., Kalofonos, C., Timotheadou, N., Siafaka, V., Vlahou, I., et al. (2003). Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology, 64(2), 102–110.PubMedCrossRef
15.
go back to reference Boogaerts, M., Coiffier, B., & Kainz, C. (2003). Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer, 88(7), 988–995.PubMedCrossRef Boogaerts, M., Coiffier, B., & Kainz, C. (2003). Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer, 88(7), 988–995.PubMedCrossRef
16.
go back to reference Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865–2874.PubMed Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865–2874.PubMed
17.
go back to reference de Castro, J., Ordonez, A., Isla, D., Sanchez, A., Arrivi, A., Manzano, J. L., et al. (2007). Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: Results of the NeoPrevent study. Cancer Chemotherapy and Pharmacology, 59(1), 35–42.PubMedCrossRef de Castro, J., Ordonez, A., Isla, D., Sanchez, A., Arrivi, A., Manzano, J. L., et al. (2007). Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: Results of the NeoPrevent study. Cancer Chemotherapy and Pharmacology, 59(1), 35–42.PubMedCrossRef
18.
go back to reference Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875–2882.PubMed Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875–2882.PubMed
19.
go back to reference Glaspy, J., Vadhan-Raj, S., Patel, R., Bosserman, L., Hu, E., Lloyd, R. E., et al. (2006). Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology, 24(15), 2290–2297.PubMedCrossRef Glaspy, J., Vadhan-Raj, S., Patel, R., Bosserman, L., Hu, E., Lloyd, R. E., et al. (2006). Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology, 24(15), 2290–2297.PubMedCrossRef
20.
go back to reference Cella, D. (1997). The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol, 34(3 Suppl 2), 13–19. Cella, D. (1997). The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol, 34(3 Suppl 2), 13–19.
21.
go back to reference Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63–74.PubMedCrossRef Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63–74.PubMedCrossRef
22.
go back to reference Levin, T. T., Riskind, J. H., & Li, Y. (2007). Looming threat-processing style in a cancer cohort. General Hospital Psychiatry, 29(1), 32–38.PubMedCrossRef Levin, T. T., Riskind, J. H., & Li, Y. (2007). Looming threat-processing style in a cancer cohort. General Hospital Psychiatry, 29(1), 32–38.PubMedCrossRef
23.
go back to reference Manser, R. L., Wright, G., Byrnes, G., Hart, D., Conron, M., Carter, R., et al. (2006). Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer, 53(2), 217–229.PubMedCrossRef Manser, R. L., Wright, G., Byrnes, G., Hart, D., Conron, M., Carter, R., et al. (2006). Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer, 53(2), 217–229.PubMedCrossRef
24.
go back to reference Witzig, T. E., Silberstein, P. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Mailliard, J. A., et al. (2005). Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2606–2617.PubMedCrossRef Witzig, T. E., Silberstein, P. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Mailliard, J. A., et al. (2005). Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2606–2617.PubMedCrossRef
25.
go back to reference Food and Drug Administration (FDA). (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133. Food and Drug Administration (FDA). (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.
26.
go back to reference Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N. K., et al. (2000). Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality of Life Research, 9(8), 887–900.PubMedCrossRef Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N. K., et al. (2000). Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality of Life Research, 9(8), 887–900.PubMedCrossRef
27.
go back to reference Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl 2), S125–137. Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl 2), S125–137.
28.
go back to reference Marquis, P., Arnould, B., Acquadro, C., & Roberts, W. M. (2006). Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Development Research, 67, 193–201.CrossRef Marquis, P., Arnould, B., Acquadro, C., & Roberts, W. M. (2006). Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Development Research, 67, 193–201.CrossRef
29.
go back to reference Leidy, N. K., Revicki, D. A., & Geneste, B. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health, 2(2), 113–127.PubMedCrossRef Leidy, N. K., Revicki, D. A., & Geneste, B. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health, 2(2), 113–127.PubMedCrossRef
30.
go back to reference Willke, R. J., Burke, L. B., & Erickson, P. (2004). Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Controlled Clinical Trials, 25(6), 535–552.PubMedCrossRef Willke, R. J., Burke, L. B., & Erickson, P. (2004). Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Controlled Clinical Trials, 25(6), 535–552.PubMedCrossRef
31.
go back to reference Kahneman, D., Krueger, A. B., Schkade, D. A., Schwarz, N., & Stone, A. A. (2004). A survey method for characterizing daily life experience: The day reconstruction method. Science, 306(5702), 1776–1780.PubMedCrossRef Kahneman, D., Krueger, A. B., Schkade, D. A., Schwarz, N., & Stone, A. A. (2004). A survey method for characterizing daily life experience: The day reconstruction method. Science, 306(5702), 1776–1780.PubMedCrossRef
32.
go back to reference Ware, J. E., Kosinski, M., & Keller, S. D. (1995). SF-12: How to score the SF-12 physical and mental health summary scales. Boston, MA: The Health Institute, New England Medical Center. Ware, J. E., Kosinski, M., & Keller, S. D. (1995). SF-12: How to score the SF-12 physical and mental health summary scales. Boston, MA: The Health Institute, New England Medical Center.
33.
go back to reference Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., et al. (1998). Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: Results from the IQOLA project international quality of life assessment. Journal of Clinical Epidemiology, 51(11), 1171–1178.PubMedCrossRef Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., et al. (1998). Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: Results from the IQOLA project international quality of life assessment. Journal of Clinical Epidemiology, 51(11), 1171–1178.PubMedCrossRef
34.
go back to reference World Health Organization. (1993). Indicators and strategies for iron deficiency and anemia programmes (pp. 6–10). Report of the WHO/UNICEF/UNU Consultation. Geneva, Switzerland. World Health Organization. (1993). Indicators and strategies for iron deficiency and anemia programmes (pp. 6–10). Report of the WHO/UNICEF/UNU Consultation. Geneva, Switzerland.
36.
go back to reference Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. D. Hays (Eds.), Assessing quality of life in clinical trials. New York: Oxford University Press. Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. D. Hays (Eds.), Assessing quality of life in clinical trials. New York: Oxford University Press.
37.
go back to reference McColl, E. (2005). Developing questionnaires. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (pp. 9–23). New York: Oxford University Press. McColl, E. (2005). Developing questionnaires. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (pp. 9–23). New York: Oxford University Press.
38.
go back to reference Willis, G., Reeve, B., & Barofsky, I. (2004). The use of cognitive interviewing techniques in quality-of-life and patient-reported outcomes assessment. In J. Lipscomb, C. Gotay, & C. Synder (Eds.), Outcomes assessment in cancer: measures, methods and applications. Cambridge, UK: Cambridge University Press. Willis, G., Reeve, B., & Barofsky, I. (2004). The use of cognitive interviewing techniques in quality-of-life and patient-reported outcomes assessment. In J. Lipscomb, C. Gotay, & C. Synder (Eds.), Outcomes assessment in cancer: measures, methods and applications. Cambridge, UK: Cambridge University Press.
39.
go back to reference Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94(2), 528–538.PubMedCrossRef Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94(2), 528–538.PubMedCrossRef
40.
go back to reference Harper, P. & Littlewood, T. (2005). Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology, 69(Suppl 2), 2–7. Harper, P. & Littlewood, T. (2005). Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology, 69(Suppl 2), 2–7.
41.
go back to reference Brown, D. J., McMillan, D. C., & Milroy, R. (2005). The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer, 103(2), 377–382.PubMedCrossRef Brown, D. J., McMillan, D. C., & Milroy, R. (2005). The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer, 103(2), 377–382.PubMedCrossRef
42.
go back to reference Mancuso, A., Migliorino, M., De Santis, S., Saponiero, A., & De Marinis, F. (2006). Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of Oncology, 17(1), 146–150.PubMedCrossRef Mancuso, A., Migliorino, M., De Santis, S., Saponiero, A., & De Marinis, F. (2006). Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of Oncology, 17(1), 146–150.PubMedCrossRef
43.
go back to reference Vogelzang, N. J., Breitbart, W., Cella, D., Curt, G. A., Groopman, J. E., Horning, S. J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Seminars in Hematology, 34(3 Suppl 2), 4–12. Vogelzang, N. J., Breitbart, W., Cella, D., Curt, G. A., Groopman, J. E., Horning, S. J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Seminars in Hematology, 34(3 Suppl 2), 4–12.
44.
go back to reference Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394–403.CrossRef Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394–403.CrossRef
45.
go back to reference Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211–1220.PubMedCrossRef Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211–1220.PubMedCrossRef
46.
go back to reference Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342–2349.PubMedCrossRef Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342–2349.PubMedCrossRef
47.
go back to reference Cella, D., Lai, J. S., & Stone, A. (2010). Self-reported fatigue: One dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Support Care Cancer. Cella, D., Lai, J. S., & Stone, A. (2010). Self-reported fatigue: One dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Support Care Cancer.
49.
go back to reference Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K. & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl 1), 22–34. Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K. & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl 1), 22–34.
Metagegevens
Titel
The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy
Auteurs
Leah Kleinman
Katy Benjamin
Hema Viswanathan
Maria Stoeckl Mattera
Linda Bosserman
Douglas W. Blayney
Dennis A. Revicki
Publicatiedatum
01-09-2012
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 7/2012
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-0034-1

Andere artikelen Uitgave 7/2012

Quality of Life Research 7/2012 Naar de uitgave